Withdrawal of Terodiline: A Tale of Two Toxicities

Pharmacovigilance: Second Edition

Volumn , Issue , 2007, Pages 109-136

  Shah, Rashmi R ^a  

^a NONE

Author keywords

Electrophysiological basis of torsade de pointes; Polymorphic CYP2D6 mediated stereoselective metabolism; Prenylamine induced proarrhythmias; Stereoselectivity in proarrhythmic potential; Terodiline induced proarrhythmias

Indexed keywords

EID: 84889392607     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059210.ch10     Document Type: Chapter

References (113)

1. Abinader EG, Shahar J (1983) Possible female preponderance in prenylamine-induced 'torsade de pointes' tachycardia. Cardiology 70: 37-40.
2. Anderson ME, Al-Khatib SM, Roden DM, Califf RM; Duke Clinical Research Institute/American Heart Journal Expert Meeting on Repolarization Changes (2002) Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 144: 769-81.
3. Andersson KE (1984) Clinical pharmacology of terodiline. Scand J Urol Nephrol Suppl 87: 13-20.
4. Andersson KE, Ekstrom B, Mattiasson A (1988) Actions of terodiline, its isomers and main metabolite on isolated detrusor muscle from rabbit and man. Pharmacol Toxicol 63: 390-5.
5. Andrews NP, Bevan J (1991) Torsade de pointes and terodiline. Lancet 338: 633.
6. Anon (1987) Cardiotoxicity of astemizole in overdose-Dosing is critical. Current Problems Issue 19, pp. 1-2. London: Committee on Safety of Medicines.
7. Anon (1988) Prenylamine withdrawn in UK. Scrip (England), No. 1300, p. 26.
8. Anon (1991a) Terodiline (Micturin): Adverse cardiac reactions. Dear Doctor/Pharmacist letter dated 25 July 1991. London: Committee on Safety of Medicines.
9. Anon (1991b) Withdrawal of terodiline. Current Problems, Issue 32, pp. 1-2. London: Committee on Safety of Medicines.
10. Anon (1993a) Effects of terodiline on urinary incontinence among older non-institutionalised women. Terodiline in the Elderly American Multicenter Study Group. J Am Geriat Soc 41: 915-22.
11. Anon (1993b) Clinical investigation of chiral active substances. CPMP Guideline (CPMP/3501/91). In: The Rules Governing Medicinal Products in the European Union EUDRALEX, Vol. 3C: Efficacy Guidelines. Brussels: European Commission, pp. 381-91. [http://pharmacos.eudra.org/F2/eudralex/vol-3/pdfs-en/3c c29aen.pdf] [Accessed on 23 October 2005].
12. Anon (1995) ICH Note for Guidance on The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions (ICH E1A). Committee for Proprietary Medicinal Products (CPMP/ICH/375/95). London: EMEA, 1 June 1995. [http://www.emea.eu.int/pdfs/human/ich/037595en.pdf] [Accessed on 23 October 2005].
13. Anon (1997a) Points to consider: The assessment of the potential for QT interval prolongation by noncardiovascular medicinal products. Committee for Proprietary Medicinal Products (CPMPl986l96). London: EMEA, 17 December 1997 [http://www.emea.eu.int/pdfs/human/swp/098696en.pdf] [Accessed on 23 October 2005].
14. Anon (1997b) Note for guidance on the investigation of drug interactions. Committee for Proprietary Medicinal Products (CPMP/EWP/560l95). London: EMEA, 17 December 1997 [http://www.emea.eu.int/pdfs/human/ ewp/056095en.pdf][Accessed on 23 October 2005].
15. Anon (2004) ICH Note for Guidance on Planning Pharmacovigilance Activities (ICH E2E). Committee for Proprietary Medicinal Products (CPMP/ICH/5716/03). London: EMEA, 1 December 2004 [http://www.emea. eu.int/pdfs/human/ich/571603en.pdf] [Accessed on 23 October 2005].
16. Anon (2005a) ICH Note for Guidance on The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmacueticals (ICH S7B). Committee for Proprietary Medicinal Products (CHMP/ICH/423/02). London: EMEA, 25 May 2005 [http://www.emea.eu.int/pdfs/human/ich/042302en.pdf] [Accessed on 23 October 2005].
17. Anon (2005b) ICH Note for Guidance on The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs (ICH E14). Committee for Proprietary Medicinal Products (CHMP/ICH/2/04) London: EMEA, 25 May 2005 [http://www.emea.eu.int/pdfs/human/ich/000204en.pdf] [Accessed on 23 October 2005].
18. Anson BD, Weaver JG, Ackerman MJ, et al. (2005) Blockade of HERG channels by HIV protease inhibitors. Lancet 365: 682-6.
19. Antzelevitch C (2004) Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem? J Electrocardiol 37 (Suppl): 15-24.
20. Antzelevitch C (2005) Modulation of transmural repolarization. Ann N Y Acad Sci 1047: 314-23.
21. Aptula AO, Cronin MT (2004) Prediction of hERG K+ blocking potency: application of structural knowledge. SAR QSAR Environ Res 15: 399-411.
22. Aronov AM (2005) Predictive in silico modeling for hERG channel blockers. Drug Discov Today 10: 149-55.
23. Bayer R, Schwarzmaier J, Pernice R (1988) Basic mechanism underlying prenylamine-induced torsade de pointes: differences between prenylamine and fendiline due to basic actions of the isomers. Curr Med Res Opin 11: 254-72.
24. Boyd G (1990) A correction to 'An apparent fatal overdose of terodiline'. J Anal Toxicol 14: 194.
25. Brynne N, Dalen P, Alvan G, et al. (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 63: 529-39.
26. Brynne N, Forslund C, Hallen B, et al. (1999) Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 48: 564-72.
27. Castenfors H, Hedenstiarna G, Glenne PO (1975) Pilot study of the effects of terodiline chloride (Bicor) in obstructive pulmonary disease. Eur J Clin Pharmacol 8: 197-200.
28. Cattini RA, Makin HL, Trafford DJ, Vanezis P (1989) An apparent fatal overdose of terodiline. J Anal Toxicol 13: 110-12.
29. Clarke A, Deeks JJ, Shakir SAW (2006) An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 29: 175-81.
30. Connolly MJ, Astridge PS, White EG, et al. (1991) Torsade de pointes, ventricular tachycardia and terodiline. Lancet 338: 344-5.
31. Davis SW, Brecker SJ, Stevenson RN (1991) Terodiline for treating detrusor instability in elderly patients. BMJ 302: 1276.
32. De Abajo FJ, Rodriguez LA (1999) Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol 47: 307-13.
33. Dessertenne F (1966) La tachycardie ventriculaire a deux foyers oppocees variable [Article in French]. Arch Mal Coeur Vaiss 59: 263-72.
34. Fenichel RR, Malik M, Antzelevitch C, et al. (2004) Druginduced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15: 475-95.
35. Ficker E, Kuryshev YA, Dennis AT, et al. (2004) Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66: 33-44.
36. Fischer-Rasmussen W (1984) Evaluation of long-term safety and clinical benefit of terodiline in women with urgency/urge incontinence. A multicentre study. Scand J Urol Nephrol Suppl 87: 35-47.
37. Fleckenstein A (1983) History of calcium antagonists. Circ Res 52 (2 Pt 2): 13-16.
38. Ford GA, Wood SM, Daly AK (2000) CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br J Clin Pharmacol 50: 77-80.
39. Fossa AA, Depasquale MJ, Raunig DL, et al. (2002) The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. J Pharmacol Exp Ther 202: 828-33.
40. Fung MC, Hsiao-hui Wu H, Kwong K, et al. (2000) Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades-1969-98. Pharmacoepidemiol Drug Saf 9 (Suppl 1): S24.
41. Geelen P, Drolet B, Rail J, et al. (2000) Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 102: 275-7.
42. Gietl Y, Spahn H, Knauf H, Mutschler E (1990) Single and multiple dose pharmacokinetics of R-(-)-and S-(+)-prenylamine in man. Eur J Clin Pharmacol 38: 587-93.
43. Hall GC, Chukwujindu J, Richardson J, et al. (1993) Micturin (terodiline) hydrochloride, torsade de pointe and other arrhythmias-a study using the VAMP database. Pharmacoepidemiol Drug Saf 2: 127-32.
44. Hallen B, Bogentoft S, Sandquist S, et al. (1989) Tolerability and steady-state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence. Eur J Clin Pharmacol 36: 487-93.
45. Hallen B, Gralls M, Brotell H, Stromberg S (1990) Pharmacokinetics of terodiline and a major metabolite in dogs with a correlation to a pharmacodynamic effect. Pharmacol Toxicol 66: 373-81.
46. Hallen B, Gabrielsson J, Palmer L, Ekstrom B (1993) Pharmacokinetics of R)+)-terodiline given intravenously and orally to healthy volunteers. Pharmacol Toxicol 73: 153-8.
47. Hallen B, Karlsson MO, Stromberg S, Noren B (1994) Bioavailability and disposition of terodiline in man. J Pharmaceut Sci 83: 1241-6.
48. Hallen B, Gabrielsson J, Nyambati S, et al. (1995) Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites. Pharmacol Toxicol 76: 171-7.
49. Hanley SP, Hampton JR (1983) Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial. Eur Heart J 4: 889-93.
50. Hanrahan JP, Choo PW, Carlson W, et al. (1995) Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol 5: 201-9.
51. Hartigan-Go K, Bateman ND, Daly AK, Thomas SHL (1996) Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther 60: 89-98.
52. Hashimoto K, Nakagawa Y, Nabata H, Imai S (1978) In vitro analysis of Ca-antagonistic effects of prenylamine as mechanisms for its cardiac actions. Arch Int Pharmacodyn Ther 273: 212-21.
53. Haverkamp W, Breithardt G, Camm AJ, et al. (2000) The potential for QT prolongation and proarrhythmia by nonantiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Eur Heart J 21: 1216-31.
54. Hoglund P, Paulsen O, Bogentoft S (1989) No effect of terodiline on anticoagulation effect of warfarin and steady-state plasma levels of warfarin enantiomers in healthy volunteers. Ther Drug Monit 11: 667-73.
55. Husted S, Andersson KE, Sommer L, Ostergaard JR (1980) Anticholinergic and calcium antagonistic effects of terodiline in rabbit urinary bladder. Acta Pharmacol Toxicol (Copenh) 46 (Suppl 1): 20-30.
56. Inman W, Clarke J, Wilton L, et al. (1993) PEM Report No 2: Terodiline. Pharmacoepidemiol Drug Saf 2: 287-319.
57. Iravani VJ, Melville GN (1975) Effect of terodiline on bronchial muscles and on tracheobronchial clearance in the rat [Article in German]. Arzneimittelforschung 25: 415-17.
58. Jones SE, Ogura T, Shuba LM, McDonald TF (1998) Inhibition of the rapid component of the delayed-rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline. Br J Pharmacol 125: 1138-43.
59. Joshi A, Dimino T, Vohra Y, et al. (2004) Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J Electrocardiol 37(Suppl): 7-14.
60. Kaden F, Kubler W (1977) [Recurrent atypical ventricular tachycardia 'torsade de pointes' following lidoflazine administration] [Article in German]. Verh Dtsch Ges Inn Med 83: 1596-7.
61. Kang J, Chen XL, Wang H, et al. (2004) Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 308: 935-40.
62. Karlen B, Andersson KE, Ekman G, et al. (1982) Pharmacokinetics of terodiline in human volunteers. Eur J Clin Pharmacol 23: 267-70.
63. Katchman AN, Koerner J, Tosaka T, et al. (2006) Comparative evaluation of hERG currents and QT intervals following challenge with suspected torsadogenic and non-torsadogenic drugs. J Pharmacol Exp Ther 316: 1098-106.
64. Kuryshev YA, Ficker E, Wang L, et al. (2005) Pentamidineinduced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312: 316-23.
65. Larsson-Backstrom C, Arrhenius E, Sagge K (1985) Comparison of the calcium antagonistic effects of terodiline, nifedipine and verapamil. Acta Pharmacol Toxicol 57: 8-17.
66. Layton D, Key C, Shakir SA (2003) Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future. Pharmacoepidemiol Drug Saf 12: 31-40.
67. Lindeke B, Ericsson O, Jonsson A, et al. (1987) Biotransformation of terodiline. III. Opposed stereo selectivity in the benzylic and aromatic hydroxylations in rat liver microsomes. Xenobiotica 17: 1269-78.
68. McLeod AA, Thorogood S, Barnett S (1991) Torsade de pointes complicating treatment with terodiline. BMJ 302: 1469.
69. Morganroth J, Ilson BE, Shaddinger BC, et al. (2004) Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 93: 1378-83.
70. Natsukawa T, Matsuzaki T, Hayashi S, et al. (1998) Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs. Gen Pharmacol 30: 137-42.
71. Noren B, Stromberg S, Ericsson O, Lindeke B (1989) Biotransformation of terodiline V. Stereoselectivity in hydroxylation by human liver microsomes. Chem Biol Interactions 71: 325-37.
72. Noronha-Blob L, Prosser JC, Sturm BL, et al. (1991) (+/-)-Terodiline: an M1-selective muscarinic receptor antagonist. In vivo effects at muscarinic receptors mediating urinary bladder contraction, mydriasis and salivary secretion. Eur J Pharmacol 201: 135-42.
73. Norton P, Karram M, Wall LL, et al. (1994) Randomised double-blind trial of terodiline in the treatment of urge incontinence in women. Obstet Gynecol 84: 385-91.
74. Olivier P, Montastruc J-L (2006) The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf May 15 [Epub ahead of print].
75. Oakley D, Jennings K, Puritz R, et al. (1980) The effect of prenylamine on the QT interval of the resting electrocardiogram in patients with angina pectoris. Postgrad Med J 56: 753-6.
76. Paar WD, Brockmeier D, Hirzebruch M, et al. (1990) Pharmacokinetics of prenylamine racemate and enantiomers in man. Arzneim Forsch 40: 657-61.
77. Paulussen AD, Gilissen RA, Armstrong M, et al (2004) Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 82: 182-8.
78. Peters D (1984) Terodiline in the treatment of urinary frequency and motor urge incontinence. A controlled multicentre trial. Scand J Urol Nephrol Suppl 87: 21-33.
79. Picard R, Auzepy P, Chauvin JP (1971) Syncopes a repetition an cours d'un treaement prolonge par la prenylamine (Segontine 60) [Article in French]. Presse Med 79: 145.
80. Postlind H, Danielson A, Lindgren A, Andersson SHG (1998) Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 26: 289-93.
81. Pratt CM, Hertz RP, Ellis BE, et al. (1994) Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 73: 346-52.
82. Pressler ML, Warner MR, Rubart M, et al. (1995) In vivo and in vitro electrophysiologic effects of terodiline on dog myocardium. J Cardiovasc Electrophysiol 6: 443-54.
83. Priori SG (1998) Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol 9: 1114-16.
84. Priori SG, Napolitano C, Schwartz PJ (1999) Low penetrance in the long-QT syndrome: clinical impact. Circulation 99: 529-33.
85. Recanatini M, Poluzzi E, Masetti M, et al. (2005) QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development. Med Res Rev 25: 133-66.
86. Rodenkirchen R, Bayer R, Mannhold R (1980) On the stereospecific negative inotropic action of prenylamine. Naunyn-Schmiedeberg's Arch Pharmacol 313(Suppl): R41.
87. Salle P, Rey JL, Bernasconi P, et al. (1985) Torsades de pointe. Apropos of 60 cases. Ann Cardiol Angeiol (Paris) 34: 381-8.
88. Sanguinetti MC, Mitcheson JS (2005) Predicting drughERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26: 119-24.
89. Shah RR (1999) Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction. Adverse Drug React Toxicol Rev 18: 181-233.
90. Shah RR (2000) The influence of chirality on drug development. Future Prescriber 1: 14-17.
91. Shah RR (2002) The significance of QT interval in drug development. Br J Clin Pharmacol 54: 188-202.
92. Shah RR (2004) Pharmacogenetic aspects of drug-induced torsade de pointes: Potential tool for improving clinical drug development and prescribing. Drug Saf 27: 145-72.
93. Shah RR (2005a) Drug-induced QT interval prolongation: Regulatory guidance and perspectives on hERG channel studies. In: Chadwick DJ and Goode J, eds, The hERG Potassium Channel: Structure, function and long QT syndrome. Novartis Foundation Symposium No. 266. Chichester: Wiley Publications, pp. 251-85.
94. Shah RR (2005b) Drugs, QTc interval prolongation and final ICH E14 guideline: An important milestone with challenges ahead. Drug Saf 28: 1009-28.
95. Shah RR, Hondeghem L (2005) Refining detection of druginduced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2: 758-72.
96. Shah RR, Midgley JM, Branch SK (1998) Stereochemical origin of some clinically significant drug safety concerns: lessons for future drug development. Adverse Drug React Toxicol Rev 17: 145-90.
97. Shuba LM, Kasamaki Y, Jones SE, et al. (1999) Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline. J Pharmacol Exp Ther 290: 1417-26.
98. Shryock JC, Song Y, Wu L, et al. (2004) A mechanistic approach to assess the proarrhythmic risk of QTprolonging drugs in preclinical pharmacologic studies. J Electrocardiol 37(Suppl): 34-9.
99. Staffa JA, Jones JK, Gable CB, et al. (1995) Risk of selected serious cardiac events among new users of antihistamines. Clin Ther 17: 1062-77.
100. Stewart DA, Taylor J, Ghosh S, et al. (1992) Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 42: 577-80.
101. Surawicz B (1989) Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations? J Am Coll Cardiol 14: 172-84.
102. Thomas SH, Higham PD, Hartigan-Go K, et al. (1995) Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 74: 53-6.
103. Thomas SHL, Hartigan-Go K (1996) Disposition of R)+)-and S)-)-terodiline in healthy man. lin Pharmacol Ther 59: 160(PII-6).
104. Tomaselli GF, Zipes DP (2004) What causes sudden death in heart failure? Circ Res 95: 754-63.
105. Veldhuis GJ, Inman WHW (1991) Terodiline and torsades de pointes. BMJ 303: 519.
106. Volperian VR, Zhou Z, Mohammad S, et al. (1996) Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 28: 1556-61.
107. Waldo AL, Camm AJ, deRuyter H, et al. for the SWORD Investigators (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348: 7-12.
108. Webster R, Allan G, Anto-Awuakye K, et al. (2001) Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. Xenobiotica 31: 633-50.
109. Wibell L (1968) Terodiline in angina pectoris-a controlled study of a new drug. Acta Soc Med Upsal 73: 75-80.
110. Wild RN (1992) Micturin and torsade de pointes-experience of a post-marketing alert. Pharmacoepidemiol Drug Saf 1: 147-50.
111. Yamada H, Dahl ML, Lannfelt L, et al. (1998) CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 54: 479-81.
112. Yang P, Kanki H, Drolet B, et al. (2002) Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105: 1943-8.
113. Yoshihara H, Yasumoto R, Kishimoto T, et al. (1992) Clinical study of terodiline hydrochloride for the treatment of urinary frequency and urinary incontinence, and its cardiovascular adverse effect [Article in Japanese]. Hinyokika Kiyo 38: 967-72.